Parameter used in model | Value | Low range of sensitivity analyses | High range of sensitivity analyses | Distribution used in probabilistic analysis | Reference nos. |
---|---|---|---|---|---|
HR for death, by no. of years after ACS | |||||
< 5 | 4.39 | 1.11 | 17.39 | Log-normal | 20 |
5-10 | 3.1 | 0.93 | 10.33 | Log-normal | 20 |
10-15 | 2.25 | 0.81 | 6.23 | Log-normal | 20 |
15-20 | 2.17 | 0.80 | 5.88 | Log-normal | 20 |
20-25 | 2.07 | 0.79 | 5.43 | Log-normal | 20 |
25-30 | 1 | NA | NA | NA | Assumption |
HR for death in the presence of heart failure relative to its absence | 8.22 | 7.49 | 9.01 | Log-normal | 21 |
HR for death with clopidogrel relative to single antiplatelet | 0.93 for 12 mo | 0.79 | 1.08 | Log-normal | 22 |
HR for death with prasugrel relative to clopidogrel | 0.95 | 0.78 | 1.16 | Log-normal | 4, 5 |
HR for death with ticagrelor relative to clopidogrel | 0.78 | 0.69 | 0.90 | Log-normal | 4, 6 |
HR for ACS with ASA and clopidogrel relative to ASA alone | 0.77 for 12 mo post-ACS | 0.67 | 0.89 | Log-normal | 22 |
HR for ACS with prasugrel relative to clopidogrel | 0.75 | 0.66 | 0.85 | Log-normal | 4, 5 |
HR for ACS with ticagrelor relative to clopidogrel | 0.84 | 0.74 | 0.94 | Log-normal | 4, 6 |
OR for stent thrombosis with single antiplatelet relative to clopidogrel | 13.70 for 6 mo post-ACS | 4.04 | 46.68 | Log-normal | 23 |
OR for stent thrombosis with prasugrel relative to clopidogrel | 0.47 | 0.35 | 0.63 | Log-normal | 4, 5 |
OR for stent thrombosis with ticagrelor relative to clopidogrel | 0.74 | 0.58 | 0.95 | Log-normal | 4, 6 |
OR for major bleeding with single antiplatelet relative to clopidogrel | 0.88 | 0.48 | 1.64 | Log-normal | 22 |
OR for major bleeding with prasugrel relative to clopidogrel | 1.46 | 1.15 | 1.85 | Log-normal | 4, 5 |
HR for major bleeding with ticagrelor relative to clopidogrel | 1.09 | 0.92 | 1.14 | Log-normal | 4, 6 |
Note: ACS = acute coronary syndrome, ASA = acetylsalicylic acid, HR = hazard ratio, NA = not available, OR = odds ratio.